ASCO 2021 | OlympiA: adjuvant olaparib following chemo significantly improves IDFS

Evandro de Azambuja, MD, PhD, L’Universite Libre de Bruxelles, Brussels, Belgium, talks on the results of the OlympiA trial (NCT02032823), a randomized Phase III study enrolling patients with germline BRCA mutant and HER2 negative high-risk early breast cancer after primary local treatment and adjuvant or neoadjuvant chemotherapy. In this patient population, adjuvant olaparib following adjuvant or neoadjuvant chemotherapy significantly improved invasive disease-free survival and distant disease-free survival with acceptable toxicity in patients with germline BRCA mutant and high-risk HER2-negative early breast cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.